Prelude Therapeutics (PRLD) Change in Acquisitions & Divestments (2022 - 2026)

Prelude Therapeutics has reported Change in Acquisitions & Divestments for 5 years, with the latest figure at $8.5 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 88.15% year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.2 million (down 48.87% YoY) and the FY2025 annual result came in at $154.4 million, up 7.48% from the prior year.
• Change in Acquisitions & Divestments grew to $8.5 million in Q1 2026 per PRLD's latest filing, from $6.4 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $81.4 million in Q3 2022 and troughed at $6.4 million in Q4 2025.
• A 5-year average of $41.2 million and a median of $40.1 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2023 and 2026: Change in Acquisitions & Divestments soared 95.01% in 2023, then sank 88.15% in 2026.
• Over 5 years, Change in Acquisitions & Divestments stood at $35.0 million in 2022, then jumped by 95.01% to $68.2 million in 2023, then plunged by 56.78% to $29.5 million in 2024, then sank by 78.3% to $6.4 million in 2025, then soared by 32.8% to $8.5 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $8.5 million, $6.4 million, and $40.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.